Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery

Short-term Investigation of Resveratrol on Lipid Turnover in Morbidly Obese Women Undergoing Gastric Bypass Surgery. Effects on Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism and Liver VLDL-triglyceride Uptake.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01826279

Enrollment

Registered

2013-04-08

Start date

2013-05-31

Completion date

2014-08-31

Last updated

2014-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, Gastric bypass surgery, Resveratrol, Insulin sensitivity, Lipid turnover, VLDL-triglyceride uptake, Liver

Brief summary

The purpose of this study is to investigate potential metabolic effects of resveratrol in morbidly obese women undergoing gastric bypass surgery. The investigators hypothesize that resveratrol will: * Decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion * Decrease hepatic and adipose tissue VLDL-TG uptake * Increase insulin sensitivity The investigators will look at changes in: * Lipid turnover (VLDL-TG kinetics, palmitate kinetics,calorimetry) * VLDL-TG uptake in different tissues (subcutaneous femoral adipose tissue, subcutaneous abdominal adipose tissue, visceral adipose tissue and liver tissue) * Insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp) * Regulation of liver fat handling * Lipoprotein lipase activity and fat cell size (abdominal and femoral adipose tissue)

Interventions

DIETARY_SUPPLEMENTResveratrol

500mg 3 times daily for 1 month

OTHERPlacebo

1 placebo tablet 3 times daily for 1 month

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

25 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Female * 25-60 years * Obesity (BMI \> 35 kg/m2) * Have at least one element of the metabolic syndrome either hypertension and/or hypercholesterolemia (high triglyceride, low HDL-cholesterol) * Undergoing gastric bypass surgery * Written informed consent

Exclusion criteria

* Any other relevant disease (e.g. diabetes, thyroid or parathyroid disease, heart, kidney or liver disease) * May have arthrosis or depression * Any present or previous malignancy * History of smoking * Alcohol dependency (more than 14 units of alcohol per week) * Participation in studies with radioactive isotope within the last six months * Hemoglobin under the normal range regarding to sex (under 7.3 mmol/l for women)

Design outcomes

Primary

Measure	Time frame	Description
Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance	1 month	\- changes from baseline after treatment with either resveratrol or placebo
Hepatic and adipose VLDL-TG uptake	1 month	\- changes in VLDL-TG uptake in resveratrol group and placebo group

Secondary

Measure	Time frame	Description
Basal and insulin stimulated free fatty acid (FFA) and glucose turnover	1 month	\- changes from baseline after treatment with either resveratrol or placebo
VLDL-TG oxidation	1 month	\- changes from baseline after treatment with either resveratrol or placebo
Regulation of liver fat handling	1 month	\- changes in regulation of liver fat handling in resveratrol group and placebo group

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026